Related Experiment Video

Updated: Jul 26, 2025

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.4K

P53/MDM2 Complex-Based Targeted Strategies in Colon Adenocarcinoma

Athanasios Niotis1, Evangelos Tsiambas2, Dimitrios Dimitroulis3

  • 1Second Department of Propedeutic Surgery, 'Laiko' General Hospital, Medical School, National and Kapodistrian University, Athens, Greece. athanasiosniotis@gmail.com.

Acta Medica Academica
|June 16, 2023
PubMed

Insights

The TP53 tumor suppressor gene is crucial in colon adenocarcinoma. MDM2 oncogene overexpression in this cancer directly impacts p53 oncoprotein levels, affecting cell cycle regulation and apoptosis.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • The TP53 tumor suppressor gene is critical in carcinogenesis, regulating cell cycle checkpoints and apoptosis.
  • TP53 is frequently mutated or epigenetically altered in epithelial malignancies, including colon adenocarcinoma.
  • Mouse Double Minute 2 Homolog (MDM2) is a proto-oncogene that negatively regulates p53 activity.

Purpose of the Study:

  • To review the mechanisms of TP53/MDM2 deregulation.
  • To analyze the impact of this deregulation on colon adenocarcinoma.
  • To understand the p53-MDM2 auto-regulatory pathway in this cancer.

Main Methods:

  • Literature review of molecular mechanisms.
  • Analysis of gene interactions in colon adenocarcinoma.
  • Focus on the TP53-MDM2 pathway.

Main Results:

  • TP53 controls cell cycle (G1/S, G2/M) and apoptosis.
  • MDM2 acts as a negative regulator of p53, repressing transcription and promoting degradation.
  • MDM2 overexpression in colon adenocarcinoma directly affects p53 oncoprotein levels.

Conclusions:

  • TP53 and MDM2 play significant roles in colon adenocarcinoma development.
  • Deregulation of the TP53/MDM2 pathway is a key event in this cancer.
  • Understanding this pathway offers insights into potential therapeutic targets.
Keywords:
CarcinomaColonGeneticsImmunohistochemistryp53-MDM2

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.8K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K